Sandia Investment Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Sandia Investment Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-442,622	Closed	-$4.61M	–	174
2023 Q4	$4.61M	Sell	442,622 -28,378	-6%	-$91.6K	3.17%	8
2023 Q3	$4.91M	Sell	471,000 -29,000	-6%	-$295K	1.33%	21
2023 Q2	$5.17M	Sell	500,000 -126,038	-20%	-$1.29M	1.14%	24
2023 Q1	$6.34M	Hold	626,038	–	–	1.16%	23
2022 Q4	$6.23M	Buy	+626,038	New	+$6.18M	1.09%	32

Other funds holding NKGN

Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TCM

Towneley Capital Management Laguna Hills, California $509M AUM 17.24% 1-Year Est. Return

Sandia Investment Management's NKGN Position: Q1 2024 in Review

Sandia Investment Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2024, closing a stake of 442,622 shares — an estimated $4.61M sold.

Sandia Investment Management first reported a position in NKGN in Q4 2022 and held it in 5 quarters. The position peaked at $6.34M in Q1 2023. 13 funds tracked by Wall St. Rank hold NKGN as of Q1 2024.

Sandia Investment Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Sandia Investment Management sold 442,622 NKGen Biotech, Inc. Common Stock shares in Q1 2024, an estimated $4.61M.
Sandia Investment Management first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
Sandia Investment Management's NKGen Biotech, Inc. Common Stock position peaked at $6.34M in Q1 2023.
13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2024.

Based on Sandia Investment Management's 13F filing for Q1 2024, filed 15 May 2024.